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Original ArticleThe translational regulator FMRP controls lipid
and glucose metabolism in mice and humansAntoine Leboucher 1,9, Didier F. Pisani 2, Laura Martinez-Gili 3, Julien Chilloux 3, Patricia Bermudez-Martin 1,
Anke Van Dijck 4, Tariq Ganief 5, Boris Macek 5, Jérôme A.J. Becker 6, Julie Le Merrer 6, R. Frank Kooy 4,
Ez-Zoubir Amri 2, Edouard W. Khandjian 7,8, Marc-Emmanuel Dumas 3, Laetitia Davidovic 1,*ABSTRACT
Objectives: The Fragile X Mental Retardation Protein (FMRP) is a widely expressed RNA-binding protein involved in translation regulation. Since
the absence of FMRP leads to Fragile X Syndrome (FXS) and autism, FMRP has been extensively studied in brain. The functions of FMRP in
peripheral organs and on metabolic homeostasis remain elusive; therefore, we sought to investigate the systemic consequences of its absence.
Methods: Using metabolomics, in vivo metabolic phenotyping of the Fmr1-KO FXS mouse model and in vitro approaches, we show that the
absence of FMRP induced a metabolic shift towards enhanced glucose tolerance and insulin sensitivity, reduced adiposity, and increased b-
adrenergic-driven lipolysis and lipid utilization.
Results: Combining proteomics and cellular assays, we highlight that FMRP loss increased hepatic protein synthesis and impacted pathways
notably linked to lipid metabolism. Mapping metabolomic and proteomic phenotypes onto a signaling and metabolic network, we predicted that
the coordinated metabolic response to FMRP loss was mediated by dysregulation in the abundances of speciﬁc hepatic proteins. We experi-
mentally validated these predictions, demonstrating that the translational regulator FMRP associates with a subset of mRNAs involved in lipid
metabolism. Finally, we highlight that FXS patients mirror metabolic variations observed in Fmr1-KO mice with reduced circulating glucose and
insulin and increased free fatty acids.
Conclusions: Loss of FMRP results in a widespread coordinated systemic response that notably involves upregulation of protein translation in
the liver, increased utilization of lipids, and signiﬁcant changes in metabolic homeostasis. Our study unravels metabolic phenotypes in FXS and
further supports the importance of translational regulation in the homeostatic control of systemic metabolism.
Crown Copyright  2019 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The Fragile X Mental Retardation Protein (FMRP) is an RNA-binding
protein, which associates with polyribosomes to regulate mRNA
translation together with its homologues FXR1P and FXR2P [1e4]. A
current model states that FMRP exerts repressive activity on translation
by reversibly stalling ribosomes on its target mRNA [5,6]. So far, FMRP
functions and the mRNAs it targets have been mostly explored in the
context of the central nervous system (CNS). Indeed, inactivation of the
X-linked FMR1 gene, which encodes FMRP, is associated with neu-
rodevelopmental defects, intellectual disability, and autism spectrum
disorders in Fragile X Syndrome (FXS), a syndrome affecting 1:6,000
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www.molecularmetabolism.commodels [9,10] to show that loss of FMRP expression affects the
translation of a wide range of mRNA, compromising brain translation
homeostasis with deleterious consequences on synaptic plasticity and
thus on behavior [4,11].
Despite the wide expression of FMRP in peripheral tissues [12,13],
thus far, the consequences of its absence outside the CNS are only
starting to be elucidated. In dfmr1-KO Drosophila, the loss of FMRP
was shown to elevate insulin signaling in the brain and intestine,
inducing developmental defects in those organs [14e16]. Another
study in the Drosophila model of FXS, highlighted reduced whole-
body carbohydrate and lipid stores, hypersensitivity to starvation,
and altered mitochondrial functions [17]. Although no overt meta-
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Original Articlemodel (Fmr1-KO1) [9], the Fmr1/Fxr2 double KO mouse displayed
increased glucose tolerance and insulin sensitivity, reduced
adiposity, and reduced circulating glucose [18]. Finally, independent
clinical studies reported reduced levels of lipids, including choles-
terol, in FXS patients compared to healthy controls [19e21]. These
data supported possible functions for FMRP in the control of glucose
and lipid metabolism, but mechanisms by which FMRP could impact
metabolism and its mRNA targets in peripheral organs remain mostly
unknown.
Here, we demonstrated that loss of FMRP in mice markedly
impacted glucose and lipid metabolism. We further showed that loss
of FMRP elevates hepatic protein synthesis and that FMRP likely
controls the translation of key hepatic proteins involved in lipid
metabolism. Finally, we provided clinical evidence that circulating
metabolic markers were altered in FXS patients as compared to
healthy controls.
2. MATERIALS AND METHODS
Detailed experimental procedures are available in the Supplemental
Information Appendix.
2.1. Animal procedures
Fmr1-KO2 mice described in [10] were housed in a temperature (22e
24 C) and hygrometry (70e80%)-controlled room with a 12-h lighte
dark cycle (lights on at 07:00) and fed on standard chow (reference
4RF25, Mucedola). All the described experiments were performed on
male littermates at 4-months of age, with the exception of initial blood
sampling of fed animals for metabolic proﬁling (presented in Figure 1)
that was performed on 4 to 6 months-old animals.
2.2. Clinical samples
25 fragile X patients and 29 sex- and age-matched healthy subjects
were enrolled at the University of Antwerp (Antwerp, Belgium). Written
informed consent was obtained from each participant or his legal
guardian before research participation. The absence/presence of the
Fragile X full mutation in the 5’ UTR of FMR1 gene was conﬁrmed in
FXS patients by an accredited laboratory, using a CGG-repeat PCR and
Southern Blotting on DNA isolated from blood. All patients had a
number of CGG repeats above 200, yielding FMR1 gene inactivation
(Pieretti et al., 1991). To avoid stress induced by fasting to Fragile X
patients, individuals involved in the study were not advised to fast prior
to venous blood sampling.
2.3. Metabolic proﬁling
For metabolome studies in mice, blood was sampled between 9 and
11a.m., either in nonfasted animals, i.e. fed ad libitum, or after an
overnight fast. For FXS controls and patients, sera were obtained from
nonfasted individuals. NMR experiments were carried out using a
Bruker Avance spectrometer (Bruker GmbH, Rheinstetten, Germany)
operating at 600 MHz as described previously [22]. Structural
assignment was performed using data from literature, HMDB (http://
www.hmdb.ca/), S-Base (Bruker GmbH, Rheinstetten, Germany) and
in-house databases [23]. 1H NMR spectra were pre-processed and
exported into Matlab for multivariate statistical analyses using
orthogonal partial least square discriminant analysis (O-PLS-DA) as
previously reported [24].
2.4. Blood chemistry and hormones measurements
Glucose was measured using a glucometer (AccuCheck Mobile,
Roche). The determination of circulating TG, FFA, and total cholesterol2 MOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier Gwas subcontracted to the Genotoul Anexplo Platform (Toulouse,
France). Leptin and insulin were measured using dedicated ELISA kits
(MesoScaleDiscovery). TG determination in liver was performed using
a dedicated kit (Sigma Aldrich).
2.5. Insulin (ITT) and glucose tolerance tests (GTT)
These experiments were conducted according to the IMPReSS qui-
delines (International Mouse Phenotyping Resource of Standardized
Screens). Mice were respectively fasted overnight (GTT) or 6 h (ITT)
prior to i.p. injection of glucose (2 g/Kg, SigmaeAldrich) or insulin
(0.75 U/Kg, Humalog, Lilly) as per recommended procedures [25].
Glucose was measured in freely moving unrestrained animals using a
glucometer (AccuCheck Mobile, Roche) in a drop of blood obtained
after incision of the tip of the tail.
2.6. In vivo tissue insulin response measurement
Mice were fasted overnight then injected with insulin (0.75 U/Kg,
Humalog, Lilly) or saline. Five minutes after injection, mice were
sacriﬁced by cervical dislocation, and tissues were rapidly dissected
and stored at 80 C until further analyses. The western-blotting
procedure and a list of antibodies and dilutions used are provided in
Appendix.
2.7. Quantitative RT-PCR
Real-time PCR reactions procedures are detailed in Appendix. Primers
used are available in Table S6.
2.8. Microcomputed tomography analysis and adipose tissue
histology
Anesthetized animals were introduced in a SkyScan-1178 X-ray
tomograph and analyzed as previously described [26]. Epididymal
adipose tissue was ﬁxed in 4% paraformaldehyde, parafﬁn-embedded,
and stained with hematoxylin and eosin.
2.9. Lipolysis assays
For in vivo lipolysis experiments, 6 hrs-fasted Fmr1-KO and WT were
injected intraperitoneally either with saline or isoproterenol at 1 mg/kg
and blood sampled 15 min post injection. For ex vivo lipolysis exper-
iments, 6 hrs-fasted Fmr1-KO and WT mice were sacriﬁced, and intra-
abdominal white epididymal fat depots were cut in explants then
treated with 1 mM isoproterenol or vehicle. Preparation of stromal
vascular fraction (SVF) of epididymal adipose tissue was performed as
described in [27]. Adipocytes derived from hMADS cells were obtained
as described in [28,29] and transfected with anti-FMR1 or control
siRNA (Invitrogen) detailed in Appendix. Lipolysis experiments of SVF-
derived adipocytes and hMADS adipocytes were performed as
described in [27].
2.10. Indirect calorimetry
Indirect calorimetry experiments were performed using indirect calo-
rimetry chambers (Phenomaster System, TSE) at the Anexplo Genotoul
metabolic phenotyping platform (Toulouse, France).
2.11. Liver proteome analysis
Livers from 4 months-old overnight fasted animals were quickly
collected after cervical dislocation, snapped frozen in liquid nitrogen
and kept at80 C until further analysis. Proteins were digested by in-
solution digestion and measured on an EASY-nLC 1200 coupled to an
Orbitrap Elite mass spectrometer (Thermo Fisher Scientiﬁc). All ac-
quired MS data were processed with the MaxQuant software suite
[30,31] version 1.5.2.8 against the complete mouse UniProt databasembH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Fmr1-deﬁciency modiﬁes metabolic proﬁles in the fed and fasting state. (A) Orthogonal Partial Least Square Discriminant Analysis (OPLS-DA) of plasma 1H NMR
spectra from fed Fmr1-KO and WT mice. PLS components (TPred1 & TYosc1) corresponding to a combination of the initial NMR spectral variables were computed for each
individual. n ¼ 18 WT, n ¼ 19 KO. (B) Permutation testing to assess signiﬁcance of the OPLS-DA model (n ¼ 10,000 random iterations, p ¼ 0.01). (C) Pseudo-spectrum
representation of OPLS-DA model to highlight spectral regions discriminating Fmr1-KO from -WT samples. s. Positive and negative model coefﬁcients respectively correspond
to signiﬁcantly higher or lower metabolite concentrations in Fmr1-KO animals as compared to WT. 1H NMR signals corresponding to glucose, aspartate, phosphocholine, the
branched amino acids (BCAA) valine (1), isoleucine (2) and leucine (3), and broad resonances from CH3 methyl groups present in lipids are highlighted. (D) Fasting plasmatic levels
of glucose in Fmr1-KO and WT animals. Data are means  SEM; n ¼ 11 WT, n ¼ 12 KO; 2-tailed Student’s T-test: ns. (E) Fasting plasmatic levels of triglycerides (TG) in Fmr1-KO
and WT animals. Data are means  SEM; n ¼ 28 WT, n ¼ 28 KO; 2-tailed Student’s T-test: *, p < 0.05. (F) Fasting plasmatic levels of total cholesterol in Fmr1-KO and WT
animals. Data are means  SEM; n ¼ 27 WT, n ¼ 28 KO; 2-tailed Student’s T-test: *, p < 0.05. (G) Fasting plasmatic levels of carnitine in Fmr1-KO and WT animals. Data are
means  SEM; n ¼ 13 WT, n ¼ 9 KO; 2-tailed Student’s T-test: *, p < 0.05. (H) Fasting plasmatic levels of free fatty acids (FFA) in Fmr1-KO and WT animals. Data are
means  SEM; n ¼ 26 WT, n ¼ 25 KO; 2-tailed Student’s T-test: *, p < 0.05. (I) Relative quantiﬁcation of 1H NMR signal from acetone (2.22 ppm) in fasting Fmr1-KO and WT
animals. Data are means  SEM; n ¼ 12 WT, n ¼ 13 KO; 2-tailed Student’s T-test: *, p < 0.05. (J) Relative quantiﬁcation of 1H NMR signal from acetoacetate (2.27 ppm) in
fasting Fmr1-KO and WT animals. Data are means  SEM; n ¼ 12 WT, n ¼ 13 KO; 2-tailed Student’s T-test: *, p < 0.05. (K) Fasting leptin in Fmr1-KO and WT animals. Data are
means  SEM; n ¼ 21 WT, n ¼ 18 KO; 2-tailed Student’s T-test: *, p < 0.05. (L) Fasting insulin in Fmr1-KO and WT animals. Data are means  SEM; n ¼ 11 WT, n ¼ 12 KO; 2-
tailed Student’s T-test: *, p < 0.05.(taxonomy ID10090). Comparison analysis for individual protein levels
between genotype was run on normal rank-based inverse log-
transformed label-free quantiﬁcation (LFQ) values and individual FDR
were calculated. GO analysis was performed using String (v10.5) [32]
and Panther (v12.0) expression analysis tools [33,34].
2.12. Puromycin-labeling of neosynthetized peptides
The hepatic cell line FL83B was transduced with a lentivirus
expressing shFmr1 or shControl and FACS-sorted based on eGFP
expression, as described in [35]. FMRP was tested using the m1C3
monoclonal antibody against FMRP in western-blotting [36] or the
avian IgY#C10 polyclonal antibodies by immunoﬂuorescence staining
[6,37,38]. The puromycin-labeling assay was performed according to
[39]. Puromycin (10 mg/mL) incorporation was performed in the
presence or absence of cycloheximide (50 mg/mL) for 15 or 30 min.
Proteins were visualized after protein transfer to nitrocellulose mem-
branes by Ponceau staining and puromycin-labeled neosynthesized
peptides were visualized by immunoblotting with anti-puromycin
12D10 antibody (Millipore) followed by HRP-coupled secondary anti-
bodies and electroluminescence detection using a Fusion VX-Imager
(Vilber). Puromycin signals were quantiﬁed in each lane by densito-
metric analysis using the ImageJ software, normalized to Ponceau
signal in the corresponding lane and then adjusted to average signal in
control cells at 15 min.
2.13. Metabolic network analysis
MetaboSignal R package [40,41] was used to build the shortest paths
network from FMRP to the metabolites of interest (Table S5), integrating
the proteins dysregulated in the liver as extra nodes to the network
(Table S6). Pivotal betweenness was then computed (Table S7).MOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier GmbH. This is an open acce
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cells or liver extracts
FL83B cells or Fmr1-WT and -KO liver were homogenized in IA buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 1.25 mM MgCl2, 0.5% NP40,
1 mM DTT, 5 U/mL RNasin (Invitrogen)). The lysates were centrifuged
at 10,000 g for 15 min at 4 C. The collected supernatant was then
raised to 400 mM NaCl and 30 mM EDTA [37]. For each IA assay,
500 mg of proteins from FL83B cells or liver extract was incubated in
the presence of 60 mg of anti-FMRP IgY#C10 antibodies or non-
immune IgY immobilized on 15 mL of anti-chicken IgY agarose
beads (Gallus Immunotech Inc.). Samples were incubated overnight
under rotation at 4 C and washed 4 times with buffer containing
10 mM Tris pH 7.4, 400 mM NaCl, 10 mM EDTA, 0.5% NP40. 1/5th of
each assay was used for immunoblot analyses using anti-FMRP
mAb1C3 antibody [36] IA-captured mRNA were then phenol-
extracted, precipitated with sodium acetate, and resuspended in wa-
ter and subjected to reverse transcription (RT) using the SuperScript III
system (Invitrogen). RT products were subjected to polymerase chain
reaction (PCR), using a PCR Master Kit (Promega) and primers detailed
in Table S8. PCR products were visualized on a 2.5% TAE agarose gel
and amplicon size was veriﬁed using the BenchTop DNA ladder
(Promega).
2.15. Statistics
Normality of data was assessed using KolmogoroveSmirnov’s test. To
compare 2 groups, 2-tailed unpaired Student’s T-test was used. For
non-normal data, raw data were log-transformed to meet normality
criteria prior to Student’s T-test. If sample size n < 8 or if normality
was not reached after log-transformation, data were analyzed using
Mann & Whitney’s non-parametrical U-test. Multiple groupss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Original Articlecomparisons were performed ANOVAs and detailed statistics appear in
Table S9. Post hoc comparisons were performed either using Sidák’s
correction for multiple comparison or Fisher’s Least Signiﬁcance Dif-
ference test (if less than 6 comparisons were performed), as stated in
the legends. Statistical signiﬁcance was set according to a two-tailed
p-value (p)< 0.05. Statistical analysis was performed using GraphPad
Prism version 6.00 for iOS (GraphPad Software, USA).
2.16. Study approvals
All animal studies were conducted in facilities accredited by legal
authorities (Direction Départementale de Protection des Populations
des Alpes-Maritimes, accreditation #C-06-152-5) using procedures
approved by the Ministère de l’Enseignement Supérieur et de la
Recherche (agreement #00788.01 and #05224.01). Samples and data
collection from Fragile X patients and controls were approved by the
medical ethics committee of the University of Antwerp in Belgium
(agreement #B300201523589). The study was conducted in accor-
dance with statutes and regulations regarding the protection of the
right and welfare of human subjects’ participation in biomedical
research (World Declaration of Helsinki).
3. RESULTS
3.1. Fmr1-deﬁciency alters plasmatic metabolites in FXS mouse
model
To study the potential impact of Fmr1-deﬁciency on general metabolic
homeostasis, we used proton nuclear magnetic resonance (1H NMR)
spectroscopy to proﬁle the plasma metabolome of 4-months old Fmr1-
WT and -KO male littermates fed ad libitum. Supervised multivariate
statistical modelling of 1H NMR data indicated that Fmr1-KO animals
displayed a characteristic plasmatic metabolic signature, signiﬁcantly
distinct from controls (Figure 1A,B). In Fmr1-KO plasma, we identiﬁed
a signiﬁcant decrease in signals from glucose, paralleled by an in-
crease in signals from branched chain amino acids, aspartate, and
phosphocholine (Figure 1C). -CH3 resonances from fatty acid (FA)
methyl groups atw0.9 ppm [42] were also signiﬁcantly increased in
Fmr1-KO animals compared to WT (Figure 1C). These results suggest
that Fmr1-deﬁciency induces possible dysregulations of glucose and
lipid metabolism observable in the fed state.
We then examined the levels of a number of metabolic markers after
an overnight fast. Fasting glycemia appeared unaffected by Fmr1-
deﬁciency as glycemia from Fmr1-WT and KO animals were both
reached standard fasting glucose levels of 100 mg/dL (Figure 1D). In
contrast, we observed reduced circulating levels of triglycerides (TG)
and total cholesterol in fasted Fmr1-KO animals, accompanied by a
reduction in plasma carnitine, a quaternary amine involved in lipid
metabolism (Figure 1EeG). Conversely, we observed signiﬁcant in-
creases in free FA (FFA) and 1H NMR signals from the ketone bodies
(KB) acetone and acetoacetate (Figure 1HeJ). Finally, we highlighted
that Fmr1-deﬁciency reduced the fasting circulating levels of the
metabolic hormones leptin and insulin (Figure 1K,L). Collectively, these
variations in metabolic markers both in the fasted and fed state pointed
towards dysregulations in glucose and lipid homeostasis in Fmr1-KO
mice.
3.2. Fmr1-deﬁciency enhances glucose tolerance and insulin
response
To further explore these dysregulations, we challenged energy ho-
meostasis in Fmr1-WT and -KO littermates by performing glucose and
insulin tolerance tests (GTT and ITT, respectively). After an overnight or
a 6 h fast, fasting glycemia was comparable for both genotypes (T0,4 MOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier GFigure 2A,B). During the course of the GTT, there was a signiﬁcant
effect of genotype on glycemia over time (Figure 2A). Post injection of
glucose, glycemia was signiﬁcantly lower in Fmr1-KO animals at 30,
45 and 60 min, when compared to WT animals (Figure 2A). During ITT,
there was also a signiﬁcant effect of genotype on glycemia over time
after insulin injection. At 90 and 120 min, glycemia of Fmr1-KO ani-
mals were signiﬁcantly lower than in Fmr1-WT controls (Figure 2B).
Cumulative glycemia calculated over the course of the GTT and ITT
were also signiﬁcantly decreased in Fmr1-KO animals (Figure 2C,D).
We further investigated the insulin response at the molecular level in
Fmr1-KO and WT liver. Injection of a bolus of insulin triggered acti-
vation and autophosphorylation of the insulin receptor (InsR) in the
liver, leading to an increased phosphorylation at Tyr1146 and Tyr1150/
1151 in both groups. In Fmr1-KO animals, the phosphorylation of InsR
was increased both in basal conditions and upon insulin injection when
compared to Fmr1-WT liver (Figure 2E). We then monitored the
phosphorylation status of Akt at Ser473. Following insulin injection, the
increase in Akt phosphosphorylation was signiﬁcantly steeper in the
Fmr1-KO liver (Figure 2E). These data suggested that loss of FMRP in
the liver was accompanied by an increased response to insulin
stimulation.
3.3. Fmr1-deﬁciency reduces adiposity and shifts metabolism
towards a higher use of lipid as energy substrates
As several classes of circulating lipids were impacted in Fmr1-KO mice
(Figure 1C,EeK) and leptin was reduced, we then sought to investigate
the impact of Fmr1-deﬁciency on adipose tissue, the main tissue for
lipid storage, as well as a site of expression for FMRP (Figure S1). We
used mCT X-ray tomography and showed that Fmr1-deﬁciency
differentially affected intra-abdominal adipose tissue (IAAT) and sub-
cutaneous adipose tissue (SCAT). The volume of IAAT was signiﬁcantly
reduced by 53.4% in Fmr1-KO animals, whilst SCAT was not affected
(Figure 3A). Further, fat pads of Fmr1-KO mice displayed smaller
adipocytes, with a reduced average surface as compared to control
animals (Figure 3B,C). Considering that adipocytes had a spherical
shape, we extrapolated their volume from the adipocyte area measures
and estimated that the mean adipocyte volume was decreased by
40.1% in Fmr1-KO animals (mean WT adipocyte
volume ¼ 1.76  0.05  104 mm3 vs. mean KO adipocyte
volume¼ 1.052 0.17 104 mm3). This was within the range of the
total WAT volume ratio (53.4%, Figure 3A) and suggests that the total
number of adipocytes is likely preserved in the absence of FMRP.
In parallel, we showed that Fmr1-KO and WT WAT express similar
mRNA levels for the adipocyte precursor marker Pdgfra [43], sug-
gesting that the adipocyte precursor pool is not impacted in WAT
(Figure S2A). Also, FMRP expression increased upon differentiation of
adipocytes derived from the stromal vascular fraction (SVF) of WAT
(Figure S2B). However, analysis of SVF-derived Fmr1-KO adipocytes
did not reveal clear adipogenesis defects when compared to Fmr1-WT
adipocytes (Figure S2C). In addition, human multipotent adipose-
derived stem (hMADS) cells repressing FMR1 did not display alter-
ations in the course of differentiation or expression of the mature
adipocyte markers PLIN1 and FABP4 (Figure S3A,B). Thus, the
reduction in fat mass observed in Fmr1-KO animals appeared unlikely
to be due to impaired adipogenesis but rather to reduced fat storage in
adipocytes in vivo. We also observed a reduction in hepatic tri-
glycerides storage in Fmr1-KO animals as compared to controls
(Figure S4).
Reduced fat storage both in liver and WAT could reﬂect a higher
consumption of lipids as energetic substrate in Fmr1-deﬁcient
animals. We therefore used indirect calorimetry chambers tombH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Fmr1-deﬁciency improves glucose tolerance and insulin sensitivity in
liver. (A) Glucose tolerance test (GTT) in Fmr1-KO and WT animals. Data are
means  SEM; n ¼ 9 WT, n ¼ 9 KO; 2-way ANOVA: p(Genotype) ¼ 0.0034,
p(Time) < 0.0001, p(Interaction) < 0.0001; Sidák’s post hoc tests for genotype-wise
comparisons: *, p < 0.05, ****, p < 0.0001. (B) Insulin tolerance test (ITT) in Fmr1-KO
and WT animals. Data are means  SEM; n ¼ 8 WT, n ¼ 8 KO; 2-way ANOVA:
p(Genotype) ¼ 0.0117, p(Time) < 0.0001, p(Interaction) ¼ 0.0134; Sidák’s post hoc
tests for genotype-wise comparisons: **, p < 0.01. (C) Cumulative glycemia over the
3 h course of GTT. Data are means  SEM; n ¼ 9 WT, n ¼ 9 KO; 2-tailed Student’s T-
test: **, p < 0.01. (D) Cumulative glycemia over the 3 h course of ITT. Data are
means  SEM; n ¼ 8 WT, n ¼ 8 KO; 2-tailed Student’s T-test: *, p < 0.05. (E)
Western-blot and densitometric analysis of insulin receptor (InsR) and Akt phosphor-
ylation status in liver from Fmr1-KO and WT animals injected with saline or insulin.
Densitometric analysis is presented as means  SEM of phosphoproteins signals ratios
relative to total protein, all signals being normalized to b-actin. InsR-Saline: n ¼ 6
animals/group, InsR-Insulin: n ¼ 5 animals/group; 2-way ANOVA:
p(Genotype) ¼ 0.0027, p(Treatment) < 0.0001, p(Interaction) ¼ 0.7424; Fisher’s LSD
post hoc tests for genotype-wise comparisons: *, p < 0.05. Akt: n ¼ 5 animals/group;
2-way ANOVA: p(Genotype) ¼ 0.0215, p(Treatment) < 0.0001,
p(Interaction) ¼ 0.0924; Fisher’s LSD post hoc tests for genotype-wise comparisons:
**, p < 0.01.measure circadian ingestive behavior, activity, O2 consumption,
and CO2 production. No signiﬁcant variations in drinking water
intake, food consumption, or total cumulative activity were
detected in Fmr1-KO animals over the course of indirect calo-
rimetry recordings (Figure S5AeD). Furthermore, Fmr1-deﬁciency
did not affect the energetic expenditure (EE) and its average over
24 h (Figure S5E,F). The respiratory exchange rate (RER), which
provides information about metabolic substrate utilization (lipid or
carbohydrate), was calculated by dividing the volume of CO2
produced (VCO2) over the volume of oxygen consumed (VO2) [44].
The RER proﬁle of Fmr1-KO animals over 24 h appeared shifted
towards lower RER values (Figure 3D). Furthermore, its averageMOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier GmbH. This is an open acce
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controls (Figure 3E), indicating that Fmr1-deﬁciency contributes to
shift metabolism towards an enhanced utilization of lipid substrates
as energetic substrate.
3.4. Fmr1-deﬁciency increases lipolysis in adipocytes
In white adipose tissue (WAT), fat accumulation is regulated by acti-
vation of b-adrenergic receptors, which elicits intracellular TG hydro-
lysis and release of glycerol and FFA to the general circulation. We
monitored lipolysis in vivo in Fmr1-KO and WT littermates in basal
conditions and upon systemic injection of isoproterenol, a pan b-
adrenergic receptor agonist. Isoproterenol treatment induced an in-
crease in peripheral plasma glycerol release in both Fmr1-WT and -KO
mice. Independently of isoproterenol treatment, glycerol release was
signiﬁcantly increased in Fmr1-deﬁcient animals (Figure 4A). We
mirrored those results in WAT explants from Fmr1-KO and WT animals
(Figure 4B). This suggests a constitutive overactivation of lipolysis in
the absence of FMRP. Also, in Fmr1-KO SVF-derived adipocytes, there
was a signiﬁcant increase in glycerol release when isoproterenol was
applied, suggestive of a higher sensitivity to b-adrenergic receptor
agonists (Figure 4C). Finally, we performed time-course experiments of
isoproterenol-induced lipolysis in hMADs transiently transfected with a
siRNA that efﬁciently repressed FMR1 mRNA (Figure S3B). As a
readout of lipolysis, in addition to glycerol release, we monitored
intracellular TG and FFA release in the medium (Figure 4D). In both
siFMR1 and siCtl-transfected cells, isoproterenol treatment impacted
intracellular TG levels (Figure 4D). After an initial phase of intracellular
TG depletion, de novo TG synthesis took over and likely accounted for
the progressive recovery in TG levels, hindering the identiﬁcation of a
signiﬁcant effect of FMR1-knockdown over the course of the experi-
ment (Figure 4D). In contrast, when considering FFA and glycerol
release induced by isoproterenol treatment, there was a signiﬁcant
impact of FMR1-knockdown (Figure 4D). By 120 min, siFMR1-trans-
fected adipocytes had released signiﬁcantly more glycerol and FFA
than siCtl-transfected adipocytes. These data collectively suggest that
loss of FMRP overactivates the b-adrenergic response and increases
lipolysis, both in mouse and human adipocytes.
3.5. The absence of FMRP leads to profound changes in the
hepatic proteome and increases hepatic protein synthesis
Since FMRP is expressed in the liver (Figure S1), a key organ for the
regulation of both glucose and lipid homeostasis, we reasoned that
molecular changes in the hepatic proteome could help reﬁne the
molecular events underlying the broad metabolic effects driven by
FMRP loss. We used quantitative Mass Spectrometry (MS) to char-
acterize the liver proteome of Fmr1-KO and WT littermates (Table S1).
The Volcano plot representing statistical signiﬁcance against fold-of-
change (FC KO vs WT) for the 2,087 detected proteins appeared
dissymmetric (Figure 5A). Among the 307 proteins with a false dis-
covery rate (FDR)  0.01 whose abundance was increased or
decreased by at least 1.5-fold (absFC  1.5; Figure 5A), there was a
shift towards higher FC with strongest changes in terms of abundance
observed for upregulated proteins in the absence of FMRP. Further
clustering analysis on these 307 proteins revealed that protein abun-
dance patterns were consistent genotype-wise (Figure 5B).
GO analysis of the 307 dysregulated proteins clearly pointed to se-
lective enrichment in pathways linked to lipid metabolism, with the
Fmr1-KO liver notably displaying increased levels of enzymes or
transporters involved in the main routes of FA catabolism (Figure 5C,
Table S2eS4). Consistent with this, there was a reduced abundance inss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 3: Fmr1-deﬁciency reduces adiposity, enhances lipolysis, and shifts metabolism towards a better utilization of lipids. (A) X-ray computerized tomography 3D
reconstruction of intra-abdominal (IAAT) and subcutaneous (SCAT) adipose tissues and calculated volumes of IAAT and SCAT in Fmr1-WT and KO animals. Data are presented as
means  SEM; n ¼ 14 WT, n ¼ 14 KO; 2-way ANOVA: p(Genotype) < 0.0001; p(AT type) < 0.0001; p(Interaction) ¼ 0.0004; LSD post hoc tests for genotype-wise comparisons:
****, p < 0.0001. (B) Representative sections of Fmr1-WT and KO IAAT stained with hematoxylin and eosin, black bars represent 100 mm. (C) Average adipocyte area in Fmr1-WT
and KO IAAT. Data are presented as means  SEM; n ¼ 6 WT, n ¼ 6 KO; 2-tailed Mann & Whitney U-test: *, p < 0.05. (D) Respiratory exchange rate (RER) follow-up over 24 h in
4 months-old Fmr1-KO and WT mice. Data are means  SEM every 10 min; n ¼ 8 WT, n ¼ 10 KO. (E) Average RER over 24 h in Fmr1-KO and WT mice. Data are means  SEM;
n ¼ 8 WT, n ¼ 10 KO; 2-tailed Student’s T-test: *, p < 0.05.
Original Articleproteins involved in lipid storage and formation of lipoprotein particles
in the absence of FMRP (Figure 5C, Table S2eS4), in agreement with
the signiﬁcant reduction in hepatic TG content in Fmr1-KO liver
(Figure S4). This supported that molecular changes in the liver in the
absence of FMRP could participate to metabolic phenotypes linked to
lipids in Fmr1-KO animals. In contrast to the numerous pathways
linked to lipid metabolism highlighted with the GO analysis, only one
pathway related to glucose was signiﬁcantly enriched “starch and
glucose metabolism” (Figure 5C, Table S3).
Besides clear overrepresentation of pathways involved in lipid meta-
bolism, the primary enriched pathways involved ribosome, RNA
translation, RNA-binding proteins, and amino-acyl-tRNA biosynthesis
(Figure 5C, Table S2eS4). Notably, core ribosomal proteins and
translation elongation factors were markedly upregulated in the6 MOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier Gabsence of FMRP (Table S2eS4). We reasoned these changes could
reﬂect a possible increase in hepatic translation in the absence of
FMRP. We therefore monitored protein synthesis in the FL83B murine
hepatocyte cell line by labeling neosynthesized polypeptides with
puromycin [39]. We inactivated FMRP expression by lentiviral trans-
duction of an shRNA directed against Fmr1. Transduced cells
expressing the shFmr1 or control shCtl were selected based on their
co-expression of eGFP. Immunoﬂuorescence staining using the avian
IgY#C10 antibodies revealed a strong reduction of FMRP expression in
shFmr1 cells as compared to shCtl cells, while the signal from the
ribosomal protein S6 remained unaffected (Figure 5D). Western blot
analysis of FMRP expression conﬁrmed that this repression is stable
over passages in shFmr1-transduced cells (Figure S6A). Puromycin
labeling of neosynthesized peptides was strongly decreased when thembH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Fmr1-deﬁciency increases lipolysis in murine and human adipocytes. (A) Glycerol release in serum as readout of lipolysis in Fmr1-KO and WT animals before and
15 min after injection of isoproterenol (Iso). Data are presented as means  SEM; n ¼ 13 WT, n ¼ 12 KO; 2-way ANOVA: p(Genotype) ¼ 0.0327; p(Treatment) < 0.0001;
p(Interaction) ¼ 0.4161; LSD post hoc tests for genotype-wise comparisons: *, p < 0.05. (B) Glycerol release as readout of lipolysis following treatment with Iso in ex-vivo culture
supernatant of epididymal white adipose tissue (WAT) explants. Data were normalized to individual WAT explant weight and presented as means  SEM; n ¼ 8/condition; 3-way
ANOVA: p(Genotype) < 0.0001, p(Treatment) < 0.0001, p(Time) < 0.0001, p(Genotype  Treatment) ¼ 0.4884, p(Genotype  Time) < 0.0001,
p(Treatment Time)< 0.0001, p(Genotype Treatment Time)¼ 0.5818; Sidák’s post hoc tests for genotype-wise comparisons: **, p< 0.01; p****,<0.0001. (C) Glycerol release
as readout of lipolysis following treatment with Iso in vitro in SVF-derived adipocytes from Fmr1-WT and KO animals. Data were normalized to protein content and presented as means
ratios relative to control WT e Iso  SEM; n ¼ 6 WT, n ¼ 6 KO; 2-way ANOVA: p(Genotype) < 0.0205; p(Treatment) < 0.0001; p(Interaction) ¼ 0.0102; LSD post hoc tests for
genotype-wise comparisons: **, p < 0.01. (D) Intracellular TG and release of glycerol and FFA following isoproterenol-induced lipolysis in human hMADS cells differentiated into
adipocytes, transiently transfected with anti-FMR1 (siFMR1) or control siRNA (siCtl). Data were normalized to protein content and presented as means ratios relative to siCtl e
Iso  SEM; n ¼ 4/condition; 2-way ANOVA: p(siRNATG) ¼ 0.7478, p(TimeTG)0.0049, p(InteractionTG) ¼ 0.9339; p(siRNAGlycerol) ¼ 0.0102, p(TimeGlycerol) < 0.0001,
p(InteractionGlycerol)¼ 0.0048; p(siRNAFFA)¼ 0.0008, p(TimeFFA)< 0.0001, p(InteractionFFA)¼ 0.0081; LSD post hoc tests for siRNA-wise comparisons: **, p< 0.01; ***, p< 0.001.translation inhibitor cycloheximide was applied, showing the speciﬁcity
of the labeling (Figure S6B). After both 15 min and 30 min of treatment,
we observed a signiﬁcant increase in puromycin incorporation in the
FL83B-shFmr1 cell line as compared to the FL83B-shCtl cell line
(Figure 5E,F). These data supported that FMRP loss exaggerated
protein synthesis in hepatocytes, in line with the shift towards higher
protein abundances in the Fmr1-KO liver and the signiﬁcant enrich-
ment in GO terms related to “Translation” or “Ribosome” highlighted in
the study of the Fmr1-KO liver proteome (Figure 5A,C, Table S3, S4).
3.6. FMRP targets hepatic mRNAs linked to lipid homeostasis
To functionally connect FMRP to the observed metabolic phenotypes
and identify the molecular pathways involved, we used a network-
based approach integrating directed metabolic and signaling net-
works [40,41]. We ﬁrst compiled an extended list of metabolites
deriving from the metabolic biomarkers identiﬁed in our initial
metabolomics and biochemical measurements (Figure 1, Table S5)
and imputed a number of interactions (Table S6). Notably, the network
displays in the inner circle close around FMRP the putative interactions
with the 307 proteins signiﬁcantly dysregulated by at least 1.5-fold in
the liver in its absence (Table S2). Then, to identify metabolic nodes
forming functional paths between FMRP and its associated metabo-
lites, we analyzed the topology of the resulting network (Figure 6A) and
derived the relative importance of each node within the network usingMOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier GmbH. This is an open acce
www.molecularmetabolism.coma measure of centrality (pivotal betweenness (PB) described in [45],
Table S7). Among the 307 dysregulated proteins in the Fmr1-KO liver,
175 displayed PB distinct from 0 (Table S7), indicating that they are
likely to contribute to the observed metabolic signature. The resulting
network (Figure 6A) highlights a number of protein nodes dysregulated
in the Fmr1-KO liver and connecting FMRP to the metabolites with
single-step paths (Figure 6A,B).
To further validate in vivo the network predictions and ascertain that
FMRP could directly regulate the translation of some pivotal proteins,
we tested whether FMRP interacted in hepatocyte with a series of
mRNAs encoding proteins appearing in the network with PB distinct
from zero and with functions directly involved in lipid and glucose
metabolism (Figure 6A,B). FMRP-associated messenger ribonucleo-
particles (mRNPs) from FL83B hepatocytes were efﬁciently trapped by
immune-afﬁnity (IA) capture, as shown by the enrichment in FMRP in
the IA preparations and the concomitant strong depletion in FMRP
signal in the post-IA supernatant (Figure 6C). Cpt1a, Slc16a1, Aldh3a2,
Abcd3, and Tecr mRNA, as well as Fmr1 mRNA, itself an extensively
validated mRNA target of FMRP [46], were detected by RT-PCR in IA-
captured FMRP complexes and not recovered in the control fraction
(Figure 6D). In contrast, the unrelated mRNA Actb, Ckdn1a, Hprt, and
Gapdh or mRNAs encoding proteins with a null PB such as Plin3 were
not detected (Figure 6D, Figure S6C). Also, the mRNAs encoding the
pivotal proteins Agl, Gys2, or Apoa2 were not recovered in FMRP mRNPss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 5: Loss of FMRP provokes profound changes in the hepatic proteome and enhances translation. (A) Volcano plot of statistical signiﬁcance presented as -Log-10
transformed false-discovery rate (FDR) against fold-of-change for each quantiﬁed protein in Fmr1-KO and WT liver. n ¼ 5 WT, n ¼ 5 KO. Signiﬁcantly upregulated proteins and
downregulated proteins (FDR<0.01) appear respectively in red and blue. (B) Heatmap visualization and clustering analysis of signiﬁcantly affected proteins whose abundance was
increased or decreased by at least 1.5-fold (see list in SI Appendix, Table S2). n ¼ 5 WT, n ¼ 5 KO. Color code refers to the calculated z-score, missing values appear in black. (C)
Selection of GO terms signiﬁcantly enriched in the list of proteins presented in b and Table S2 (see SI Appendix) and associated adjusted p-value (Table S3, S4). (D) Immu-
noﬂuorescence analysis of FMRP expression in the FL83B hepatic cell line transduced with a virus driving the expression of a control shRNA (shCtl) or an shRNA targeting Fmr1
(shFmr1) coupled to eGFP (green). FMRP was detected with IgY#C10 anti-FMRP antibodies (red) and the ribosomal protein S6 with anti-S6 antibodies (purple). Nuclei were
counterstained with DAPI (blue) and merge images are shown in the last panel. The same exposure time was used for image captures of shFmr1- and shCtl transduced cells. (E)
Translation monitoring assay using puromycin-labeled proteins in the shFmr1- or shControl (shCtl)- inactivated cells. Cells were labeled with puromycin for 15 and 30 min. Cell
homogenates were analyzed by SDS-PAGE and proteins transferred to nitrocellulose membranes. Separated proteins were stained with Red Ponceau followed by immuno-blotting
with an anti-puromycin antibody (a-Puro) that labels neosynthesized peptides. (F) Densitometric analysis of puromycin signal in (E). Data were normalized to total protein Ponceau
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complexes, suggesting selectivity in FMRP mRNA recognition
(Figure S6C). To further validate that the identiﬁed associations also
occurred in vivo, we performed IA-capture experiments in liver ho-
mogenates obtained from Fmr1-WT and -KO mice and conﬁrmed the
presence of Cpt1a, Slc16a1, Aldh3a2, Abcd3 and TecrmRNA in FMRP-
containing mRNPs (Figure S7). These experiments suggest that FMRP
associates with mRNA encoding pivotal enzymes and transporters in
the network and likely controls their translation in the liver. This could
contribute to the lipid-related metabotypes observed in Fmr1-KO
animals.
3.7. FXS patients display reduced glycemia, insulinemia and
increased circulating FFA
To further assess the clinical relevance of the identiﬁed metabolic
effects induced by loss of FMRP in FXS mouse model, we collected
sera samples in a cohort of 25 FXS patients, bearing FMR1 full-
mutation (above 200 CGG repeats in the 5‘UTR of the gene) which
leads to FMR1 gene inactivation and loss of FMRP [47], and 29 sex and
age-matched controls (Figure S8A,B). Distributions of body mass in-
dexes were not different between patients and controls (Figure S8C).
Sera of patients and controls were collected randomly during the day,
but the distribution of sample collection time was not differing between
control and patient groups (Figure S8D). We then used 1H-NMR to
proﬁle the serum metabolome of controls and FXS patients. O-PLS-DA
modelling of 1H-NMR data showed that FXS patients display a char-
acteristic serum metabolic signature that is signiﬁcantly different from
controls (Figure 7A,B). Serum from FXS patients displayed a signiﬁcant
decrease in signals from glucose (Figure 7C,D), similarly to Fmr1-KO
animals in the nonfasted state (Figure 1C). In FXS patients, there was
also a signiﬁcant decrease in signals from glutamine and alanine,
paralleled by an increase in creatine signals (Figure 7C). Finally, FXS
patients displayed a signiﬁcant reduction in insulin levels and a sig-
niﬁcant increase in circulating FFA as compared to controls
(Figure 7E,F).
4. DISCUSSION
Here, we provide an in-depth metabolic phenotyping of the FXS mouse
model and highlight the consequences of the loss of the translational
regulator FMRP on metabolic homeostasis in mice and humans. We
further highlighted the contributing molecular mechanisms, as we
show that loss of FMRP increased hepatic synthesis of proteins notably
involved in lipid metabolism.
4.1. The absence of the translational regulator FMRP dysregulates
hepatic protein synthesis with consequences on systemic
metabolism
In this study, we demonstrate that the absence of FMRP leads to an
increase in protein synthesis, as supported by our proteomics data in
the Fmr1-KO liver in combination with quantiﬁcation of protein syn-
thesis in Fmr1-deﬁcient hepatocytes. This depicts FMRP as a regulator
of hepatic translation, in agreement with its presence on poly-
ribosomes from mouse liver [2]. Biological network integration of
metabolomics and proteomics data enabled us to identify key mRNA
targets of FMRP linked to the metabolic phenotypes observed in Fmr1-
KO animals: Cpt1a, Slc16a1, Aldh3a2, Abcd3, and Tecr. Importantly,
these mRNA were previously identiﬁed as putative FMRP targets insignal, adjusted to average signal in shCtl cells at 15 min and presented as means  cSE
p(shRNA) < 0.0001, p(Time) < 0.0001, p(Interaction) ¼ 0.4288; LSD post hoc tests for
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their association with FMRP and the overabundance of the corre-
sponding proteins in the Fmr1-KO liver. These data support the fact
that FMRP functions as a translational repressor in the liver for this
subset of mRNAs and directly controls translation of the cognate
protein. Our work indicates that loss of FMRP determines increased
abundances of key enzymes or transporters cooperating in FA hepatic
metabolism either through direct translational regulation, or indirectly
possibly through compensatory or adaptive mechanisms. Although we
cannot exclude the fact that the activity of these enzymes and trans-
porters could be downregulated to compensate for their over-
abundance, dysregulated hepatic expression of these proteins could
explain the variations in the circulating levels of a number of metab-
olites and contribute to the global metabolic changes observed in
Fmr1-KO animals. Notably, in the absence of FMRP, overabundance of
Cpt1a, the rate limiting enzyme of FA mitochondrial b-oxidation which
transfers the acyl group of LCFA-CoA conjugates onto carnitine [49],
could directly improve the mitochondrial uptake of long-chain fatty
acids and their subsequent mitochondrial b-oxidation. This is in
agreement with previous work showing that increase in CPT1A activity
enhanced b-oxidation rates both in vitro and in vivo, reduced hepa-
tocyte TG accumulation and secretion and increased KB formation
[50,51], in agreement with our ﬁndings in Fmr1-KO mice. In the
absence of FMRP, the increased synthesis of the monocarboxylate
transporter Slc16a1 [52] could also favour hepatic export of KB, the
terminal breakdown products of mitochondrial b-oxidation, contrib-
uting to elevate the circulating levels of the KB acetone and acetoa-
cetate in Fmr1-KO mice. Furthermore, overabundance of the FA
transporter Abcd3 and of the aldehyde dehydrogenase Aldh3a2 could
also be indicative of increased peroxisomal b-oxidation of lipids [53].
All these data suggest a direct link between loss of the translational
regulator FMRP in liver and lipid homeostasis. FMRP is expressed in all
peripheral tissues, except in adult muscle [13,54]. Further studies are
now required to understand the impact on translation of FMRP loss in
extra-hepatic peripheral tissues with metabolic roles, and how it could
disrupt their metabolic interplay.
4.2. The absence of FMRP perturbs key metabolic pathways
In the absence of FMRP, we also show that key metabolic signaling
pathways are over-activated: the insulin-mediated control of glucose
homeostasis and the b-adrenergic control of lipolysis. Excessive in-
sulin signaling in the brain [14,15] and in the intestine [16] was pre-
viously described in the dfmr1 FXS drosophila model and also
associated with excessive Akt phosphorylation. Our work further ex-
tends these ﬁndings to the liver in the Fmr1-KO mouse model and
suggests that FMRP is generally required for the ﬁne-tuning of the
response to insulin. Increased sensitivity to insulin in the liver could
explain the improved glucose tolerance in Fmr1-KO animals, while the
reduced circulating levels of insulin might result from a physiological
adaptation to counteract excessive insulin signaling. Defective insulin
signaling in other peripheral organs might participate to the glucose-
related phenotypes we describe in the present study. In mice, intes-
tinal gluconeogenesis is essential to maintain glycemia in the absence
of hepatic glucose production [55]. Furthermore, bone is also a tissue
exerting some control on metabolism, and notably on the insulin
system [56]. Given the fact that FMRP is not expressed in adult muscle
[13,54], we anticipate that the consequences of FMRP loss in muscleM; n ¼ 6 independent measures/group, except for WT 30 min, n ¼ 5; 2-way ANOVA:
shRNA-wise comparisons: ***, p < 0.001; ****, p < 0.0001.
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Figure 6: Metabolic network mapping links FMRP to metabolic dysregulations via speciﬁc mRNA targets involved in lipid catabolism. (A) Classes of circulating me-
tabolites and hepatic proteins signiﬁcantly dysregulated in Fmr1-KO animals were mapped onto the interactome. The resulting network allows connecting the causal protein FMRP
to the downstream metabolic consequences of its absence. (B) Pivotal proteins of the network, Log2 fold-of-change (FC) in the Fmr1-KO vs WT liver, associated adjusted p-value
(FDR) and normalized pivotal betweenness scores (PB). (C) Cell homogenates from FL83B hepatocytes (Input), immuno-afﬁnity (IA) puriﬁed complexes, captured with control IgY (IA
Ctl) or anti-FMRP IgY#C10 (IA C10) antibodies and corresponding post-IA ﬂowthrough (FT) supernatants were separated by SDS-PAGE, transferred onto a nitrocellulose membrane
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Figure 7: FMR1-deﬁciency in Fragile X Syndrome patients reduces glucose and insulin and increases circulating FFA. (A) OPLS-DA of 1H NMR spectra from sera of FXS
patients and sex-, aged-, BMI-matched controls and computation of PLS scores maximizing the segregation of the groups (TPred1 & TYosc1). Sera were collected in the fed state.
(B) Permutation testing to assess signiﬁcance of the O-PLS-DA model presented in (A) (n ¼ 10,000 random iterations, p ¼ 0.026). (C) Pseudo-spectrum representation of OPLS-DA
model coefﬁcients to highlight spectral regions responsible for discrimination between FXS and control samples. Positive and negative model coefﬁcients respectively correspond to
signiﬁcantly higher or lower metabolite concentrations in FXS patients as compared to controls. 1H NMR signals corresponding to glucose, glutamine, alanine and creatine are
highlighted. (D) Relative quantiﬁcation of the 1H NMR signal corresponding to glucose peak at 5.25 ppm in sera from controls and FXS patients. Data are means  SEM; n ¼ 28
controls, n ¼ 24 FXS patients; 2-tailed Student’s T-test on log-transformed data: *, p < 0.05. (E) Circulating levels of insulin in controls and FXS patients. Data are means  SEM;
n ¼ 29 controls, n ¼ 25 FXS patients; 2-tailed Student’s T-test on log-transformed data: *, p < 0.05. (F) Circulating levels of FFA in controls and FXS patients. Data are
means  SEM; n ¼ 28 controls, n ¼ 25 FXS patients; 2-tailed Student’s T-test on log-transformed data: *, p < 0.05.tissue would only be indirect or secondary to the alterations we
describe in the liver.
We also highlight that Fmr1-deﬁcient experimental models display
an enhancement of the badrenergic agonist-driven lipolytic
response in WAT, which could underpin the reduced adiposity inand stained with Ponceau (upper panel). IgY heavy chains and light chains are indicated b
depletion in FMRP load in the post-IA C10 ﬂowthrough with IgY#C10 (FT C10), as compared
Total RNA was extracted from the input cell lysate and IA preparations described in (C), and
IgY#C10 (IA C10) IA complexes as well as control blank PCR (Bk) performed in the absence
weights (MW) of PCR amplicons are speciﬁed on the right side.
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could enhance the bioavailability of lipid substrates for hepatic b
and uoxidation and contribute to the shift towards a higher utili-
zation of lipids substrates observed in Fmr1-KO mice using indirect
calorimetry.y an asterisk. Immunoblotting with anti-FMRP mAb1C3 antibody (lower panel). Note the
to input and control IgY IA (FT Ctl). (D) RT-PCR analysis of mRNA associated with FMRP.
used as a template for RT-PCR. PCR products obtained from input, control IgY (IA Ctl) or
of matrix were separated and visualized by agarose gel electrophoresis. The molecular
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Original Article4.3. The Fragile X family of proteins and RNA-binding proteins
have possible conserved roles in the control of metabolic
homeostasis
We show that the absence of FMRP provokes profound changes in
glucose and lipid metabolism in the Fmr1-KO2 mouse model, while no
overt metabolic alterations were previously reported in the Fmr1-KO1
mouse model of FXS [18]. Besides differences in the breeding, housing
or diet used for the Fmr1-KO1 and KO2 models, possible explanation
for this could be the age of the animals studied and different experi-
mental design for in vivo metabolic phenotyping. However, Lumaban &
Nelson showed that the Fmr1/Fxr2 double knock out mouse exhibits
metabolic abnormalities overlapping with our observations: enhanced
glucose tolerance and insulin response, hypoglycemia, and reduced
adiposity [18]. This suggests a conserved role for the Fragile X Related
family of genes in the regulation of metabolic homeostasis. In keeping
with this notion, a recent study indicates that the Drosophila FXS model
displays anomalies in energy metabolism, with decreased whole-body
glucose and lipid stores and impaired mitochondrial functions [17]. In
addition, we show both in mouse and human that FMR1-deﬁciency
impacts the circulating metabolome and notably reduces glucose and
insulin levels. This suggests that FXS may also be accompanied by yet
under reported modiﬁcations in insulin sensitivity and glucose ho-
meostasis in humans, similar to that seen in our FXS mouse model and
in FXS ﬂy model [17]. We highlighted reduced levels of FFA in FXS
patients; lower blood cholesterol was previously reported in FXS pa-
tients [19e21], and we now report it in the Fmr1-KO2 mouse model,
suggesting that lipid homeostasis is generally impacted by FMR1-
deﬁciency. Other translational regulators such as the translation initi-
ation factors EIF6 [57] and EIF4BP1 [58] or the ribosomal protein S6
kinase p70S6K [59] have previously been described as modulators of
metabolic phenotypes and notably of lipid homeostasis. In particular,
similarly to Fmr1-KO mice, S6k1-KO and Eif4bp1-KO mice have
reduced body fat mass, increased lipolysis, and decreased adipocyte
size. Our study therefore strengthens the importance of RNA-binding
proteins and translation regulators in the general control of meta-
bolic homeostasis.
4.4. Clinical relevance of ﬁndings
Regarding the clinical relevance of our ﬁndings of reduced adiposity in
FXS mouse model, there is a lack of large-scale epidemiological
studies on adiposity in the general FXS population. Although severe
obesity is reported in less than 10% of FXS patients, known as Prader
Willi-like (PWL) [60,61], obesity is not described in typical FXS patients
[7,62], such as the patients enrolled in our study. On one hand, obese
FXS patients are likely to beneﬁt at the behavioral and metabolic level
from treatment with the anti-diabetic drug metformin, as recently
shown in seven FXS cases [63]. On the other hand, we show that
typical FXS patients are likely to present metabolic phenotypes distinct
from type 2 diabetes (T2D) with reduced glycemia and insulinemia.
One study even mentioned a lower incidence of T2D in FXS population
[63]. In the same line, earlier studies have reported that FXS patients
are not prone to hyperlipidemia since they display reduced cholesterol
and TG [19e21], in agreement with our ﬁndings in FXS mouse model.
Treatment with the cholesterol-lowering agent lovastatin improved
behavioral outcome in FXS patients [64], but the authors also observed
an unexpectedly strong diminution in TG and cholesterol levels after 3
months of treatment [20,64]. This raises the issue that the possible
untoward effects of metabolic drugs should be considered in clinical
trials involving FXS patients not harbouring T2D features or
hyperlipidemia.12 MOLECULAR METABOLISM xxx (xxxx) xxx Crown Copyright  2019 Published by Elsevier G4.5. Conclusions
Our study identiﬁes metabolic phenotypes in FXS and supports a role
for FMRP-mediated translation in the homeostatic control of systemic
metabolism. Furthermore, this work underlines the importance to
further investigate the metabolic roles of translational regulators, both
in fundamental biology and from a clinical standpoint.
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